sameAs
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerIspinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaDonor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesRituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell LymphomaFlavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaFludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerMDX-010 in Treating Patients With Recurrent or Refractory LymphomaTacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerLow-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple MyelomaFludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerAlisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaDonor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid MalignanciesCyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesLenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplanVeliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsVaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaMK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or LeukemiaInfection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantTissue Collection for Studies of Lymph CancerEtoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaTreatment and Natural History Study of Lymphomatoid GranulomatosisDeferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesStudy of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaLenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersHigh-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaVorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaBendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaLenalidomide Maintenance Therapy After High Dose BEAM With or Without RituximabGamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaAR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaReduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic MalignanciesSingle or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesMethoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesNivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell LymphomasDose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantBortezomib and Filgrastim in Promoting Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Stem Cell TransplantRituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaIbrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionGenetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin LymphomaBlood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas
P1050
Q61918165-B0B85D0F-FF6D-4163-83F6-22945296868AQ61934710-BC79B0C0-5B91-4678-9561-EC492B57C340Q61936868-F1B325AD-6442-473A-A25A-1BBED7A7FDC9Q61980887-E0CD42DA-3F3D-4AE9-B3E2-110288686847Q62105023-94932A54-0DD2-4EAE-B780-405AB1014AEAQ62105038-725032A8-C3BA-4DE7-9A03-E67702613C57Q62110093-186D9AB0-CBD8-4EC5-8B46-A34055ADC014Q62110098-FE7A800B-E5CF-4D04-AD66-208C5C3F4F8AQ62110333-7444A23A-64E2-4A41-B7AB-213F6B910891Q62110790-3310006E-897F-41C9-A6FA-D9CD1F3B4014Q63317912-6ED9B508-7EB8-4BBD-842C-8E447C17E6C1Q63319629-6C977009-1F8F-46DB-90AA-6FE78E6C0365Q63320777-08803CB0-471D-4FD7-ACAD-077C6280E86CQ63322386-BA2DCD48-B0C7-408E-A8C8-553EA1416DA6Q63338899-7D6F95EE-3927-46A3-8EF0-A281C447E36EQ63340349-0A844151-A03B-499E-88C8-5FD06EFAFAFDQ63341045-5980A65B-E8C5-4CBF-B807-5828A8F8F7C7Q63572918-4F7E08B5-CFA9-4130-96EF-1A8712D98992Q63575822-B5394728-3320-48A5-85C0-689C571987E8Q63806652-A0B49DF0-79E2-4493-AB00-0DA83DC505E3Q63808143-7BB6090A-7FE8-4BC6-88B5-DAFB6DA94618Q63815432-BAA0AAEE-3365-49BE-AD51-4AB72DB28079Q63817723-5AA7243B-C319-4F0A-A4A7-7D14ED95887DQ63818387-7F6E769E-B617-45B8-873F-4CEAA31346E5Q63829689-2D61B199-D4A0-4595-BFA7-8AD66719CF8EQ63831582-4EA216E8-9FF4-4694-A231-E4A203A9719AQ63833225-44C1DF29-6735-49D6-B1FD-D8BB73E44AD8Q63835402-F20ADB95-A4D7-4664-88D5-427DC7FF8110Q63836089-971296C8-7085-4B07-A997-9343C8C55BBAQ63836492-C4BA1CE3-B74B-41C0-A708-11E1A35635ECQ63836792-3302D6AC-BE35-4F66-B54D-61CC07842494Q63838272-C7A42CAA-7677-4D1D-A8CF-06DCFE8BBE9DQ63840494-42AC4E33-4700-4DA5-AEF8-23E20CB89DEEQ64173339-3AE22923-644E-4B77-83D6-E211FC79945CQ64353364-4884052E-A891-44A4-B620-A15DB560E259Q64392725-CD84601C-20F1-4E18-9FD0-D2A423D31608Q64599977-4422315F-39A0-479E-A709-CE8EB6AFF165Q64611700-EEC468B8-B4CF-4CD1-B83C-19E3C7812854Q64625689-4AF20F36-D0A0-46B4-9C8F-27E17BF05F4CQ64634634-17E21333-A617-4CEA-8FE3-2C8C5A981E86
P1050
description
Krankheit
@de
malattia
@it
name
Granulomatosis linfomatoide
@es
Lymphomatoid granulomatosis
@en
Lymphomatoid granulomatosis
@nl
granulomatose lymphomatoïde
@fr
granulomatosi linfomatoide
@it
リンパ腫様肉芽腫症
@ja
type
label
Granulomatosis linfomatoide
@es
Lymphomatoid granulomatosis
@en
Lymphomatoid granulomatosis
@nl
granulomatose lymphomatoïde
@fr
granulomatosi linfomatoide
@it
リンパ腫様肉芽腫症
@ja
altLabel
LYG
@en
prefLabel
Granulomatosis linfomatoide
@es
Lymphomatoid granulomatosis
@en
Lymphomatoid granulomatosis
@nl
granulomatose lymphomatoïde
@fr
granulomatosi linfomatoide
@it
リンパ腫様肉芽腫症
@ja
P1995
P672
P486
P6366
P1550
P1748
P279
P2888
P2892
P31
P3827
lymphomatoid-granulomatosis
P4229
P486
P5270
MONDO:0019466
P563
P6366
2776135003
2909228671
P672
C04.557.386.480.150.600
C04.834.567
C15.604.515.569.480.150.600
C20.683.515.761.480.150.600